Article
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
The New England journal of medicine - 20 May 2004
Lynch Thomas J, Bell Daphne W, Sordella Raffaella, Gurubhagavatula Sarada, Okimoto Ross A, Brannigan Brian W, Harris Patricia L, Haserlat Sara M, Supko Jeffrey G, Haluska Frank G, Louis David N, Christiani David C, Settleman Jeff, Haber Daniel A
Abstract excerpt
BACKGROUND: Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms under...
Topics
- Adenocarcinoma
- Adult
- Aged
- Aged, 80 and over
- Amino Acid Sequence
- Antineoplastic Agents
- Base Sequence
- Carcinoma, Non-Small-Cell Lung
- DNA Mutational Analysis
- Drug Resistance, Neoplasm
- Epidermal Growth Factor
- ErbB Receptors